Atrium Therapeutics stock: Corventis trial doses first patient
Published on 11/20/2026 at 01:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAtrium advances its cardiac pipeline
- The first patient has been dosed in the Phase 1/2 Corventis trial for PRKAG2 syndrome.
- Atrium expects initial proof-of-concept data in the second half of 2027.
- The company says its pro-forma cash balance supports operations through 2028.
Atrium Therapeutics said on November 12 that it had dosed the first patient in Corventis, its Phase 1/2 trial of ATR 1072 for PRKAG2 syndrome. In its PR Newswire release, the company said initial proof-of-concept data are expected in the second half of 2027.
Clinical milestone and financial update
Corventis is designed to evaluate ATR 1072 in people with PRKAG2 syndrome, a genetic cardiomyopathy. The study is planned to enroll approximately 37 participants and will assess safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy trends.
Atrium reported third-quarter collaboration revenue of 15.3 million US dollars, including a 15.0 million US dollar milestone from its research collaboration and license agreement with Bristol Myers Squibb. Research and development expenses were 13.8 million US dollars, while general and administrative expenses were 8.2 million US dollars. The company posted a net loss of 4.3 million US dollars for the quarter.
Cash supports upcoming development
Atrium said cash, cash equivalents and short-term investments totaled 232.1 million US dollars at September 30. Including the BMS milestone and net proceeds from a 50.0 million US dollar private placement completed in October, the pro-forma cash balance was 293.6 million US dollars. Management expects that balance to fund operations through 2028.
Atrium targets genetic heart disease
Atrium Therapeutics develops RNA medicines intended to treat the underlying causes of cardiomyopathies. Its platform delivers RNA therapeutics directly to heart muscle, with ATR 1072 focused on PRKAG2 syndrome and ATR 1086 aimed at PLN cardiomyopathy. The company is based in San Diego and is building a specialist position in precision cardiology through targeted delivery technology originally designed at Avidity Biosciences.
Atrium Therapeutics at a glance
- Company: Atrium Therapeutics, Inc.
- ISIN: US05370A1088
- Ticker: RNA
- Exchange: Nasdaq
- Headquarters: San Diego, United States
- Lead program: ATR 1072 for PRKAG2 syndrome
US equities provide the broader market setting through the S&P 500.
